ArcticZymes granted NOK 1.65 million funding from Innovation Norway for a SAN-HQ upscaling project

Tromsø, Norway, 20th May 2020 – Biotec Pharmacon (OSE: Biotec) announces that its subsidiary, ArcticZymes AS, has been granted up to NOK 1.65 million by Innovation Norway for a project to increase the manufacturing scale of its SAN-HQ enzyme ArcticZymes’ Salt Active Nuclease High Quality (SAN-HQ) enzyme offers gene therapy and vaccine customers a more cost effective and technically superior …

Biotec Pharmacon – Notice of Annual General Meeting

The annual general meeting (“AGM”) in Biotec Pharmacon will be held on Thursday 14. May 2020 at 13.00 CET at SIVA Innovation Centre (Linken), Sykehusvegen 23, Tromsø. Due to the Corona pandemic, a number of measures are being taken to prevent the virus from spreading. The measures are implemented to ensure the health and safety of the Company’s employees, shareholders …

ArcticZymes launches dsDNase Triton FREE

ArcticZymes AS is pleased to announce the launch of dsDNase Triton FREE. This launch is a continuing step towards maintaining a completely EU REACH compliant product portfolio after Triton X-100 becomes subject to authorisation in January 2021 and facilitate a smooth transition for our existing dsDNase customers. dsDNase Triton FREE is available for shipping. You can request a quote by contacting …

ArcticZymes presents joint poster with the Cell and Gene Therapy Catapult

SAN HQ developed by ArcticZymes has quickly found its place as a valuable tool in manufacture of gene-delivery vehicles (viral vectors) applicable in gene therapy. In cooperation with the Cell and Gene Therapy Catapult, a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK, ArcticZymes presented a scientific …